For two decades, the idea of a cancer vaccine built for one person, from the specific mutations in that person's own tumor, has lived mostly in laboratories and small early trials. On August 19, Merck and Moderna reported that the idea cleared the bar that matters most. Their Phase 3 trial in high-risk melanoma met its main goal and a key secondary one, the companies said, with improvements they described as statistically significant and clinically meaningful [1]. It is the first time a personalized mRNA cancer vaccine has succeeded in a late-stage, randomized trial.
The trial, called INTerpath-001, enrolled 1,137 patients whose stage IIB to stage IV melanoma had been completely surgically removed, the point at which the cancer looks gone but often is not [1]. Patients received either the individualized vaccine plus the immunotherapy Keytruda or Keytruda alone. The combination met the primary endpoint, recurrence-free survival, meaning it lengthened the time patients lived without the cancer returning, and it met a secondary endpoint, distant metastasis-free survival, the time before the cancer spread to distant organs [1]. The companies did not release the underlying Phase 3 numbers. They said the detailed results will be presented at an upcoming international medical meeting and shared with regulatory authorities [1].
The therapy is called intismeran autogene, known during development as V940 or mRNA-4157. It is not one shot for everyone. Each dose is manufactured for a single patient, coded with the neoantigens, the mutation-specific flags found in that patient's tumor, so the immune system is trained to recognize that cancer and nothing else. Keytruda takes the brakes off the immune response; the vaccine points it at a target. The two were designed to work together.
That design is why this is being read as a platform milestone rather than a single drug approval. No individualized mRNA cancer vaccine had ever met the goals of a randomized, late-stage trial before. The same approach is now in a broader program, INTerpath, that Merck describes as nine Phase 2 and Phase 3 trials spanning melanoma, non-small cell lung cancer, bladder cancer and kidney cancer [1]. A win in resected melanoma is the first domino, and the companies are betting the mechanism carries to other tumors.
The confidence behind that bet comes from an earlier study. Merck says the Phase 3 readout builds on the Phase 2b KEYNOTE-942 trial, also known as mRNA-4157-P201, whose five-year follow-up was presented at the 2026 ASCO Annual Meeting [1]. In that earlier trial, the vaccine plus Keytruda showed a 49 percent lower risk of recurrence or death, a hazard ratio of 0.51 with a 95 percent confidence interval of 0.294 to 0.887, and a 59 percent lower risk of distant metastasis or death, a hazard ratio of 0.411 with a confidence interval of 0.200 to 0.843, compared with Keytruda alone [1]. Those Phase 2b figures are what the larger Phase 3 was built to confirm. The Phase 3 trial has now met its endpoints, though its own hazard ratios have not been disclosed.
The people this is for are concrete. A patient with stage IIB or higher melanoma has had the tumor cut out and has been told the odds of it returning are not small. Keytruda already helps that group, and many still relapse. For them, a treatment that further lowers the chance of recurrence is the difference between years of watching and waiting and a longer stretch of being simply well.
What Merck and Moderna released is a topline press release, not a published paper, and it deserves to be read as one. The full data have not been peer-reviewed, and the announcement left out the numbers that would let outsiders judge how large and how durable the Phase 3 benefit is: the hazard ratios, the median follow-up, the actual count of relapses in each arm, and how the 1,137 patients divided between the two groups. The therapy is not approved by the FDA. A vaccine manufactured one patient at a time also raises a question the trial does not answer, which is what it will cost and whether the system to build and deliver a bespoke vaccine can reach the patients who need it. The result is real. The distance between a strong Phase 3 signal and a treatment sitting in a clinic is also real.
Professor Georgina Long of the Melanoma Institute Australia led the study. On the evidence her trial produced, the caution and the good news point the same direction. This is the first time the personalized mRNA idea has held up when it was tested the hard way, at scale, against a real comparator, with recurrence as the thing being counted.
